Copyright HMP Communications
|
|
- Audrey Sims
- 6 years ago
- Views:
Transcription
1 Explaining the Discrepancy Between Lower Patency and Higher Limb Salvage Rates After Revascularization for Critical Limb Ischemia Carly N. Richards, MD; Peter A. Schneider, MD From the Division of Vascular Therapy, Kaiser Foundation Hospital and Department of Surgery, Tripler Army Medical Center, Honolulu, Hawaii. ABSTRACT: In patients treated for critical limb ischemia (CLI), limb salvage rates are consistently better than patency rates. This has prompted some to question whether perfusion really matters. In an effort to better explain this very reproducible phenomenon, our analysis suggests that the difference between patency and limb salvage rates can be explained by a number of factors, the most important of which are the effects of reintervention and the severity of tissue loss present in the CLI population under study. VASCULAR DISEASE MANAGEMENT 2016;13(11):E245-E251 Key words: critical limb ischemia, peripheral vascular disease, vascular intervention A tenet of vascular care is that tissue needs adequate perfusion to survive. This is so integral to our thinking about vascular disease that it is only rarely questioned. One exception to this has been in the management of critical limb ischemia (CLI). In patients treated for CLI, limb salvage rates are consistently better than patency rates. 1-4 This has prompted some to question whether perfusion really matters. In an effort to better explain this very reproducible phenomenon, our analysis suggests that the difference between patency and limb salvage rates can be explained by a number of factors, the most important of which are the effects of reintervention and the severity of tissue loss present in the CLI population under study. These two factors, along with a few other facets that are unique to this complicated CLI cohort, help to explain the nature of the difference between the higher limb salvage rates and lower patency rates after revascularization. BACKGROUND The presence of lower patency rates with discordant higher limb salvage rates in the same patient groups has prompted clinicians in the field to ask why this occurs and even to doubt the value of perfusion in CLI. Limb salvage is much more readily apparent to patients than patency. If perfusion is a prerequisite to healing the threatened limb, it would make more sense if patency correlated well with limb salvage. This variance between lower patency and higher limb salvage rates is not an isolated issue, but rather a strong trend seen in the literature. 1-4 A meta-analysis by Romiti et al summarized more than 60% of the articles published between 2000 and 2006 on infrapopliteal angioplasty Vascular Disease Management November
2 Table 1: Primary Patency and Limb Salvage Rates in Selected Studies Institution or Study Name (no. patients) Primary Patency (%) for chronic CLI. The study showed a limb salvage rate of 86% and primary patency rate of 58% at 1 year. 5 These findings are in keeping with more current literature as well. In an effort for the study of CLI to move forward, a practical discussion of this seeming discrepancy is worthwhile. 1-4 There is an important caveat in the patency vs limb salvage discussion. Limb salvage is a very clear-cut endpoint: either the patient has undergone a major limb amputation above or below the knee or not. Any broad discussion of patency must include details of the technique of measuring patency. It is extremely variable from study to study. Even common measurement techniques have not been standardized. However, even when combining studies that utilize ankle brachial index (ABI), physical exam, Doppler, duplex, computed tomography angioplasty (CTA), and angiography, the gap may change a bit but the same wide variance between limb salvage and patency rates have been demonstrated. 1-5 The efficacy of angioplasty for limb salvage has been confirmed through large clinical trials. The British Bypass versus Angioplasty in Severe Ischemia of the Leg (BASIL) trial highlighted the value of angioplasty in limb salvage. The trial enrolled 452 patients with severe limb ischemia due to infrainguinal disease. The Limb Salvage (%) Gap (Primary Patency % - Limb Salvage %) Pitt 3 (111) Massachusetts General Hospital 11 (409) Leipzig 1 (62) IN.PACT DEEP 2 (358) Cornell 12 (106) Range (%) investigators found that after several years of follow-up that neither bypass first nor angioplasty first were more successful at limb salvage, although bypass was more expensive. 6 This finding has been echoed by multiple other nonrandomized studies. However, in many CLI studies there is likely a significant selection bias in treatment. Patients who are too ill for an infrainguinal bypass will be recommended for angioplasty by default while patients with diffuse, multilevel disease are more likely to be offered a bypass, especially if they have major foot damage. 7,8 This selection bias does alter results somewhat but gives little explanation for the issue at hand. LIMB SALVAGE IS A COMPLICATED PROCESS Limb salvage in CLI is a highly complex process, and its solution is multifaceted. A profound degree of ischemia is usually required to produce CLI but multiple factors must be reversed or at least successfully managed to heal the limb; patency is just one of those. Medical issues such as renal insufficiency, malnutrition, untreated infection, and chronic nonambulatory status are related to poor wound healing, independent of vascular factors. The treatment of any wound requires control of diabetes, proper nutrition, wound care, and various mechanical off-loading techniques. 9,10 The discrepancy in limb salvage and patency rates Vascular Disease Management November
3 is shown in Table 1. Although this fact is broadly identifiable in the literature, for illustrative purposes we selected a sampling of recent, well-performed, representative studies in the field. These studies are from well-known centers in the United States and the European Union that used balloon angioplasty to restore perfusion. Fernandez et al from the University of Pittsburgh evaluated the efficacy of tibial artery endovascular intervention in 111 patients with Rutherford class 4, 5, and 6 CLI. The primary patency at 1 year was 33% and the limb salvage rate was 75%. 3 Conrad et al from Massachusetts General Hospital with 409 patients demonstrated a primary patency rate of 64% with a limb salvage rate of 85%. 1,2,11 Meltzer et al from Cornell did a retrospective review of 106 patients with a primary in the short term. There are no wounds to heal, there patency of 64%, 23% lower than their limb salvage at 87%. 12 We included the IN.PACT Deep study in the analysis. This was a multicenter study conducted in the syndrome. As an added confounder, many patients with European Union that randomized patients to either diabetes and/or renal failure do not experience a rest percutaneous transluminal angioplasty (PTA) or drug pain phase prior to the initiation of tissue loss. Thus, coated balloon. Although this was a negative study (no the rest pain cohort may be predetermined to include benefit of the drug coated balloon was seen) the overall a less challenging patient population. 15,16 Studies with cohort of 358 patients received the most contemporary larger populations of Rutherford class 4 patients are and aggressive endovascular interventional care. The likely to have different outcomes than studies with a overall limb salvage rate in the entire group at 1 year predominance of patients with tissue loss. The Society was 93%. In the imaging cohort, the primary patency for Vascular Surgery staging system for CLI patients was 60% at 1 year. 2 The difference between primary includes assessment of wound, ischemia, and foot infection criteria (SVS WIfI). In the SVS WIfI scoring patency and limb salvage rates among this small group of studies mirrors the broader literature. 4,5,8 Even within system for likelihood of amputation, patients with rest this small group of recent studies, the range at 1 year in pain are considered at low or very low risk of limb the gap between limb salvage and patency is anywhere loss. 17 Zhan et al evaluated 201 patients with threatened from a low of 23% to a high of 67%. This variance is limbs. They focused on the clinical outcomes of 1-year from trials as diverse as European, American, plain old amputation-free survival (AFS) rate and wound healing balloon angioplasty, and drug-coated balloon angio- time (WHT). Each of the three WIfI categories was plasty data with enrollment sizes from 62 to over 400 patients. Clues that help explain this discrepancy are found within the complex CLI population. IMPACT OF TISSUE LOSS Part of the challenge in understanding the patencylimb salvage gap may be the inclusion of Rutherford class 4 (patients with rest pain but without tissue loss) along with Rutherford 5 and 6 patients. The degree of tissue loss correlates with the likelihood of a longer healing time as well as amputation. 9,13,14 Patients with rest pain but no tissue loss require significantly less management and reversal of other confounding variables and are significantly less likely to lose a limb is often no or minimal infection to treat, and a single level of revascularization usually resolves the clinical Vascular Disease Management November
4 Table 2: Patency-Limb Salvage Gap Compared to Rest Pain and Target Lesion Revascularization Institution or Study Gap (Primary Patency % - Rest Pain Target Lesion Rest Pain + TLR Name (no. patients) Limb Salvage %) Revascularization (TLR) (%) Pitt 3 (111) Massachusetts General Hospital 11 (409) Leipzig 1 (62) IN.PACT DEEP 2 (358) Cornell 12 (106) Range (%) (from Table 1) graded from mild to severe, and based on these findings, patients were further divided into stage 1 (very low risk) to stage 4 (high risk). Risk of amputation and WHT increased with advanced stages. This follows what one would expect clinically; patients who present with more severe tissue loss generally do worse clinically. 13 In the 2008 meta-analysis of CLI, studies that included less than 75% of patients with tissue loss had a better patency at 1 year than studies that included more than 75% of patients with tissue loss (52.5% vs 66.0%) and a better limb salvage rate (92.6% vs 86.1%). 5 Incidentally, among the representative studies in Table 1, the best correlation and the narrowest gap between primary patency and limb salvage was in the study from Cornell, which included only patients with tissue loss. 12 In the representative studies, patients with rest pain comprised up to 29% of the subjects. 1-3,11 Other tissue-related factors that may help to explain the discrepancy between limb loss and patency include degree of infection upon presentation and subsequent wound management. Both of these factors introduce significant variability into the clinical course. Infection associated with tissue loss plays a major role in the risk of limb loss. As noted above, the WIfI scoring system also takes into account the presence of infection, and it is common for patients with major tissue loss to also present with significant infection. In this case, even with adequate perfusion, advancing infection may cause further damage. Wound management is also highly variable from one practice to the next and aggressive and vigilant wound care is required in addition to perfusion to achieve wound healing. Revascularization is not expected to be productive in the face of ongoing or untreated infection. Conversely, excellent wound care using contemporary methods may be successful even if the revascularization is marginal. ROLE OF REINTERVENTION Another factor contributing to the gap between primary patency and limb salvage is that a significant portion of patients with loss of patency receive reintervention, which results in further opportunities for improved perfusion and limb salvage, but is not reflected in the primary patency data. The use of reintervention, or target lesion revascularization (TLR) within 1 year of the index procedure ranges in the cited studies from 13% to 50% (Table 2). In Table 2, the patencylimb salvage gap from Table 1 is compared with the percentage of patients in each study with rest pain (no tissue loss) and also those requiring reintervention. Vascular Disease Management November
5 Table 3: Patency-Limb Salvage Gap Compared to Rest Pain Plus Target Lesion Revascularization Institution or Study Name (no. patients) Gap (Primary Patency % - Limb Salvage %) Rest Pain + TLR Pitt 3 (111) Massachusetts General Hospital 11 (409) Leipzig 1 (62) IN.PACT DEEP 2 (358) Cornell 12 (106) Range (%) There is a substantial decline in the gap between limb salvage and patency when secondary patency is utilized. 5 In the studies from both Schmidt et al and Fernandez et al, the reintervention rate is 50%. For example, in the clinical study by Fernandez et al, using secondary patency lowers the patency-limb salvage gap from 42% to 19%. 1,3 In the meta-analysis by Romiti et al, primary patency at 1 year with PTA was 58% and secondary patency was 68%. The absolute difference between patency and limb salvage then declines significantly from 28% to 18%. 5 This could have a major impact on the perceived gap between patency and limb salvage since this patient population very often requires TLR to maintain patency and achieve healing. When the 2 factors are combined, the use of reinterventions and the inclusion of rest pain (patients without tissue loss), the gap between primary patency and limb salvage at 1 year almost completely disappears from a numerical standpoint. Table 3 demonstrates the comparison between the identified primary patency-limb salvage gap (Table 1) and the results when reintervention and non-tissue-loss patients are accounted for in the analysis of each study. 1,2,11 In 4 of the 5 representative studies, the combination of TLR and rest pain is larger than the gap between primary patency and limb salvage. In the IN.PACT Deep study, the limb salvage-patency gap was slightly larger than the combination of TLR and rest pain. It should be noted that the patency figure for the IN.PACT Deep study was derived from an imaging cohort, not from the entire study group. Going forward, our understanding of the patency-limb salvage gap must take into account the role of reintervention and tissue loss. COMPARING ANGIOPLASTY TO BYPASS STUDIES Patients with severe tissue loss are frequently directed toward bypass rather than angioplasty. After undergoing bypass, patients are less likely to require reintervention, with overall estimates of around 30% as opposed to angioplasty where up to half require reintervention Bypass series are expected to include more patients with tissue loss and a lower reintervention rate. It follows that bypass should be more likely to have a better correlation between primary patency and limb salvage and this is what is seen in the literature. 24 For instance, in Romiti et al, bypass data show a primary patency rate of 81.5% and a limb salvage rate of 88.5%. 5 Slim et al, in a contemporary bypass series, evaluated 230 patients with infrainguinal CLI and found a limb salvage rate of 83.0% at 1 year with a patency rate of 87.4%. 22 OTHER FACTORS Another issue is that if the wound heals prior to loss of patency, the patient is at a low risk of limb loss Vascular Disease Management November
6 despite a loss of patency. Although wounds in CLI patients may require many months or even a year to heal, more superficial wounds and ulcers in locations that are easily managed may heal readily with a few weeks or months of revascularization. In many studies, a substantial number of the wounds are healed within 1 year. 25 Because time to wound healing has not been well correlated with patency at the time of healing, the impact of this factor remains unknown. However, it is possible that this is a significant factor in promoting higher limb salvage rates. Some Rutherford class 4 patients may also be misdiagnosed. There is a paucity of data on the rate of potential misdiagnosis of rest pain, but not all studies include objective data proving ischemia along with the pain in these patients. The possible inclusion of patients as Rutherford class 4 who in fact have, for instance, neuropathic pain would skew the findings. 26 CONCLUSION After revascularization for CLI, limb salvage rates and primary patency rates at 1 year are significantly different, with patency rates being quite a bit lower. This can potentially be explained by considering specific factors such as the effects of both tissue loss and reintervention on the overall results of revascularization. n Editor s note: Disclosure: The authors have completed and returned the ICMJE Form for Disclosure of Potential Conflicts of Interest. The authors report no disclosures related to the content herein. Manuscript received March 28, 2016; provisional acceptance given May 20, 2016; manuscript accepted August 22, Address for correspondence: Peter A. Schneider, MD, 3288 Moanalua Road, Honolulu, Hawaii peterschneidermd@aol.com REFERENCES 1. Schmidt A, Ulrich M, Winkler B, et al. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv. 2010;76(7): Zeller T, Baumgartner I, Scheinert D, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64(15): Fernandez N, McEnaney R, Marone LK, et al. Predictors of failure and success of tibial interventions for critical limb ischemia. J Vasc Surg. 2010;52(4): Ghoneim B, Elwan H, Eldaly W, Khairy H, Taha A, Gad A. Management of critical lower limb ischemia in endovascular era: experience from 511 patients. Int J Angiol. 2014;23(3): Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47(5): Adam DJ, Beard JD, Cleveland T, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL): multicentre, randomised controlled trial. Lancet ;366(9501): Katib N, Thomas SD, Lennox AF, Yang JL, Varcoe RL. An endovascular-first approach to the treatment of critical limb ischemia results in superior limb salvage rates. J Endovasc Ther. 2015;22(4): Dosluoglu HH, Lall P, Harris LM, Dryjski ML. Long-term limb salvage and survival after endovascular and open revascularization for critical limb ischemia after adoption of endovascular-first approach by vascular surgeons. J Vasc Surg. 2012;56(2): Smith AD, Hawkins AT, Schaumeier MJ, de Vos MS, Conte MS, Nguyen LL. Predictors of major amputation despite patent bypass grafts. J Vasc Surg. 2016;63(5): Luders F, Bunzemeier H, Engelbertz C, et al. CKD and acute and long-term outcome of patients with peripheral artery disease and critical limb ischemia. Clin J Am Soc Nephrol. 2016;11(2): Conrad MF, Crawford RS, Hackney LA, et al. Endovascular management of patients with critical limb ischemia. J Vasc Surg. 2011;53(4): Meltzer AJ, Evangelisti G, Graham AR, et al. Determinants of outcome after endovascular therapy for critical limb ischemia with tissue loss. Ann Vasc Surg. 2014;28(1): Zhan LX, Branco BC, Armstrong DG, Mills JL Sr. The Society for Vascular Surgery lower extremity threatened limb classification system based on Wound, Ischemia, and foot Infection (WIfI) correlates with risk of major amputation and time to wound healing. J Vasc Surg. 2015;61(4): Nishibe T, Yamamoto K, Seike Y, et al. Endovascular therapy Vascular Disease Management November
7 for femoropopliteal artery disease and association of risk factors with primary patency: the implication of critical limb ischemia and TASC II C/D disease. Vasc Endovascular Surg. 2015;49(8): Carter SA, Tate RB. Value of toe pulse waves in addition to systolic pressures in the assessment of the severity of peripheral arterial disease and critical limb ischemia. J Vasc Surg. 1996;24(2): Liu JT, Chang CS, Su CH, Li CS. Insights into microcirculation underlying critical limb ischemia by single-photon emission computed tomography. Medicine (Baltimore). 2015;94(27):e Mills JL S, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59(1): e Mills JL S, Wixon CL, James DC, Devine J, Westerband A, Hughes JD. The natural history of intermediate and critical vein graft stenosis: recommendations for continued surveillance or repair. J Vasc Surg. 2001;33(2): ; discussion Wilson YG, Davies AH, Currie IC, et al. Vein graft stenosis: incidence and intervention. Eur J Vasc Endovasc Surg. 1996;11(2): Baril DT, Chaer RA, Rhee RY, Makaroun MS, Marone LK. Endovascular interventions for TASC II D femoropopliteal lesions. J Vasc Surg. 2010;51(6): Baril DT, Marone LK, Kim J, Go MR, Chaer RA, Rhee RY. Outcomes of endovascular interventions for TASC II B and C femoropopliteal lesions. J Vasc Surg. 2008;48(3): Slim H, Tiwari A, Ahmed A, Ritter JC, Zayed H, Rashid H. Distal versus ultradistal bypass grafts: amputation-free survival and patency rates in patients with critical leg ischaemia. Eur J Vasc Endovasc Surg. 2011;42(1): Jongsma H, Bekken JA, van Buchem F, Bekkers WJ, Azizi F, Fioole B. Secondary interventions in patients with autologous infrainguinal bypass grafts strongly improve patency rates. J Vasc Surg. 2016;63(2): Schamp KB, Meerwaldt R, Reijnen MM, Geelkerken RH, Zeebregts CJ. The ongoing battle between infrapopliteal angioplasty and bypass surgery for critical limb ischemia. Ann Vasc Surg. 2012;26(8): Kobayashi N, Hirano K, Nakano M, et al. Wound healing and wound location in critical limb ischemia following endovascular treatment. Circ J. 2014;78(7): Santilli JD, Santilli SM. Chronic critical limb ischemia: diagnosis, treatment and prognosis. Am Fam Physician. 1999;59(7): Vascular Disease Management November
Olive registry: 3-years outcome of BTK intervention in Japan. Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan
Olive registry: 3-years outcome of BTK intervention in Japan Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan What is the optimal treatment for the patient with critical limb ischemia (CLI)?
More informationJohn E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationOne Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller
One Year after In.Pact Deep: Lessons learned from a failed trial Prof. Dr. Thomas Zeller Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: x Consulting:
More informationPaclitaxel-coated versus Plain Balloon Angioplasty in the Treatment of Infrainguinal Vein Bypass Stenosis
Paclitaxel-coated versus Plain Balloon Angioplasty in the Treatment of Infrainguinal Vein Bypass Stenosis T. Hölzenbein, A. Ugurluoglu, M. Aspalter, W. Hitzl, K. Linni Dep Vascular & Endovascular Surgery
More informationMaximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia
Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia Traci A. Kimball, MD Department of Surgery Grand Rounds Septemember 13, 2010 Overview Defining Critical Limb Ischemia Epidemiology
More informationThe incidence of peripheral artery disease (PAD)
Pharmacologic Options for Treating Restenosis The role of cilostazol in the treatment of patients with infrainguinal lesions. By Osamu Iida, MD, and Yoshimitsu Soga, MD The incidence of peripheral artery
More informationStratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI?
Stratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI? Peter F. Lawrence, M.D. Gonda Vascular Center Division of Vascular Surgery
More informationEndovascular Should Be Considered First Line Therapy
Revascularization of Patients with Critical Limb Ischemia Endovascular Should Be Considered First Line Therapy Michael Conte David Dawson David L. Dawson, MD Revised Presentation Title A Selective Approach
More informationDisclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are
An initial strategy of open bypass is better for some CLI patients, and we can define who they are Fadi Saab, MD, FASE, FACC, FSCAI Metro Heart & Vascular Metro Health Hospital, Wyoming, MI Assistant Clinical
More informationSpecificities for infrapopliteal stents
Specificities for infrapopliteal stents Nicolas Diehm, M.D. Swiss Cardiovascular Center Clinical and Interventional Angiology University Hospital Bern, Switzerland Disclosures Speaker`s Bureau: MEDRAD,
More informationSurgery is and Remains the Gold Standard for Limb-Threatening Ischemia
Surgery is and Remains the Gold Standard for Limb-Threatening Ischemia Albeir Mousa, MD., FACS.,MPH., MBA Professor of Vascular and Endovascular Surgery West Virginia University Disclosure None What you
More informationCurrent Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis Osamu Iida, MD From the Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan. ABSTRACT: Approximately
More informationCase Discussion. Disclosures. Critical Limb Ischemia: A Selective Approach to Revascularization Works Best 4/28/2012. None. 58 yo M, DM, CAD, HTN
Critical Limb Ischemia: A Selective Approach to Revascularization Works Best None Disclosures Michael S. Conte MD, FACS Division of Vascular and Endovascular Surgery Co-Director, Heart and Vascular Center
More informationMaking BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD Faculty Disclosure Thomas Zeller, MD For the 12 months preceding this presentation, I disclose the following types of
More informationInterventional Treatment First for CLI
Interventional Treatment First for CLI Patrick Alexander, MD, FACC, FSCAI Interventional Cardiology Medical Director, Critical Limb Clinic Providence Heart Institute, Southfield MI 48075 Disclosures Consultant
More informationLimb Salvage in Diabetic Ischemic Foot. Kritaya Kritayakirana, MD, FACS Assistant Professor Chulalongkorn University April 30, 2017
Limb Salvage in Diabetic Ischemic Foot Kritaya Kritayakirana, MD, FACS Assistant Professor Chulalongkorn University April 30, 2017 Case Male 67 years old Underlying DM, HTN, TVD Present with gangrene
More informationAngiosome revascularization strategies in real world practice: how much difference does it make?
Angiosome revascularization strategies in real world practice: how much difference does it make? Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii Disclosure Peter A. Schneider... I have
More informationMaking the difference with Live Image Guidance
Live Image Guidance 2D Perfusion Making the difference with Live Image Guidance In Peripheral Arterial Disease Real-time results, instant assessment Severe foot complications the result of hampered blood
More information9/7/2018. Disclosures. CV and Limb Events in PAD. Challenges to Revascularization. Challenges. Answering the Challenge
Disclosures State-of-the-Art Endovascular Lower Extremity Revascularization Promotional Speaker Jansen Pharmaceutical Promotional Speaker Amgen Pharmaceutical C. Michael Brown, MD, FACC al Cardiology Associate
More informationAre DES and DEB worth the cost in BTK interventions?
Are DES and DEB worth the cost in BTK interventions? Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen, Germany -1- My Disclosures: Advisory Board: Medtronic-Invatec, Gore,
More informationAre RCT always needed: Experience with objective performance criteria (OPC)
Are RCT always needed: Experience with objective performance criteria (OPC) Peter A. Schneider, MD Krishna Rocha-Singh, MD Kaiser Foundation Hospital Honolulu, Hawaii Prarie Heart Institute Springfield,
More informationMultidisciplinary approach to BTK Y. Gouëffic, MD, PhD
Multidisciplinary approach to BTK Y. Gouëffic, MD, PhD Department of vascular surgery, University Hospital of Nantes, France Response to the increased demand of hospital care Population is aging Diabetes
More informationPATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA. Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE
PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE Disclosure Speaker name: DR. Manar Trab I have the following potential
More informationLIMB SALVAGE IN THE DIABETIC PATIENT
LIMB SALVAGE IN THE DIABETIC PATIENT WHO? HOW? BEST? DISCLOSURES Educational grant from Cook Inc OBJECTIVES Review risk stratification and staging schemes for the threatened limb Discuss current concepts
More informationClinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
More informationEndovascular treatment of infrapopliteal arteries: angioplasty vs stent in the drug-eluting era
Eur Radiol (2014) 24:793 798 DOI 10.1007/s00330-014-3094-0 VASCULAR-INTERVENTIONAL Endovascular treatment of infrapopliteal arteries: angioplasty vs stent in the drug-eluting era Fabrizio Fanelli & Alessandro
More informationBEST-CLI Trial Study Concept and Current Status
BEST-CLI Trial Study Concept and Current Status Kenneth Rosenfield, MD, MHCDS National Co-PI BEST-CLI Trial Section Head, Vascular Medicine and Intervention Institute for Heart, Vascular, and Stroke Care
More informationDo we really need a stent in long SFA lesions? No: DEB is the answer
Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany My Disclosures: Advisory Board: Medtronic-Invatec,
More informationForget about the angiosome theories. Yann Gouëffic, MD, PhD Department of vascular surgery, institut du thorax, Nantes, France
Forget about the angiosome theories Yann Gouëffic, MD, PhD Department of vascular surgery, institut du thorax, Nantes, France Disclosure of Interest Research grants /Consulting/Honoraria for - Abbott -
More informationLower Extremity Peripheral Arterial Disease: Its All About the Pulse. Spence M Taylor, M.D.
Lower Extremity Peripheral Arterial Disease: Its All About the Pulse Spence M Taylor, M.D. President, Greenville Health System Clinical University Senior Associate Dean for Academic Affairs and Diversity
More informationRecommendations for Follow-up After Vascular Surgery Arterial Procedures SVS Practice Guidelines
Recommendations for Follow-up After Vascular Surgery Arterial Procedures 2018 SVS Practice Guidelines vsweb.org/svsguidelines About the guidelines Published in the July 2018 issue of Journal of Vascular
More informationSPINACH Making Limb Salvage Salad from Spinach alone
SPINACH Making Limb Salvage Salad from Spinach alone Surgical reconstruction versus Peripheral Intervention in patients with critical limb ischemia prospective multicenter registry in Japan Nobuyoshi Azuma,
More informationKonstantinos Katsanos, MSc, MD, PhD, EBIR. Consultant Interventional Radiologist Guy's and St.Thomas' Hospitals, NHS Foundation Trust
Konstantinos Katsanos, MSc, MD, PhD, EBIR Consultant Interventional Radiologist Guy's and St.Thomas' Hospitals, NHS Foundation Trust King's Health Partners, London, United Kingdom Nothing to declare Anatomy
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationImaging Strategy For Claudication
Who are the Debators? Imaging Strategy For Claudication Duplex Ultrasound Alone is Adequate to Select Patients for Endovascular Intervention - Pro: Dennis Bandyk MD No Disclosures PRO - Vascular Surgeon
More informationAngiosome concept myth or truth? Does it make a real difference in real world cases?
Angiosome concept myth or truth? Does it make a real difference in real world cases? Osamu Iida, MD, FACC Kansai Rosai Hospital Amagasaki, Hyogo, Japan Disclosure Speaker name:... I have the following
More informationGlobal Vascular Guideline on the Management of Chronic Limb Threatening Ischemia -a new foundation for evidence-based care
Global Vascular Guideline on the Management of Chronic Limb Threatening Ischemia -a new foundation for evidence-based care Michael S. Conte MD Professor and Chief, Division of Vascular and Endovascular
More informationDiagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC
Diagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC Interventional Cardiologist/Endovascular Specialist Bradenton Cardiology Center Bradenton,
More informationPractical Point in Holistic Diabetic Foot Care 3 March 2016
Diabetic Foot Ulcer : Vascular Management Practical Point in Holistic Diabetic Foot Care 3 March 2016 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai
More informationCurrent Vascular and Endovascular Management in Diabetic Vasculopathy
Current Vascular and Endovascular Management in Diabetic Vasculopathy Yang-Jin Park Associate professor Vascular Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine Peripheral artery
More informationJanuary 23, Vascular and oncological interventional radiology Paris Descartes University
January 23, 2019 First time data release: Paclitaxel-coated balloon in below-the-knee lesions: 6-months results from the Ranger BTK single center study Dr. Costantino Del Giudice Prof Marc Sapoval Vascular
More informationEndovascular treatment (EVT) has markedly advanced,
Ann Vasc Dis Vol. 6, No. 3; 2013; pp 573 577 Online August 12, 2013 2013 Annals of Vascular Diseases doi:10.3400/avd.oa.13-00055 Original Article A Review of Surgically Treated Patients with Obstruction
More informationFabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
Don t Use Risky and Embolizing Drug Coated Balloons Below The Knee! Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More informationDCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
More informationOccluded vessels in the upper extremity are. Copyright HMP Communications
Atherectomy in the Occluded Forearm: A Case Presentation of Interosseous Ulnar Artery Treatment Dwight Dishmon, MD From the University of Tennessee Health Science Center, Memphis, Tennessee. ABSTRACT:
More informationPopliteal Bypass Versus Percutaneous Transluminal
501591SJS102410.1177/1457496913501591The treatment of occlusive superficial femoral artery diseaseh. Linnakoski, et al. 2013 ORIGINAL ARTICLE Scandinavian Journal of Surgery 102: 227 233, 2013 Comparison
More informationEvidence-Based Optimal Treatment for SFA Disease
Evidence-Based Optimal Treatment for SFA Disease Endo first Don t burn surgical bridge Don t stent if possible Javairiah Fatima, MD Assistant Professor of Surgery Division of Vascular and Endovascular
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationEndovascular Is The Way To Go: Revascularize As Many Vessels As You Can
Rafael Malgor, MD Assistant Professor of Surgery The University of Oklahoma, Tulsa Endovascular Is The Way To Go: Revascularize As Many Vessels As You Can Background Lower extremity anatomy (below the
More informationSurgical Bypass vs. Zilver PTX stent for long SFA lesions : Interim results of the ZilverPass Trial
Surgical Bypass vs. Zilver PTX stent for long SFA lesions : Interim results of the ZilverPass Trial Dr. Koen Deloose Head of Vascular Surgery AZ Sint-Blasius Dendermonde Belgium Disclosure slide Speaker
More informationIs there still any space left for DES in the BTK area??? (Angiolite BTK trial, 6 month Data)
Is there still any space left for DES in the BTK area??? (Angiolite BTK trial, 6 month Data) (Angiolite BTK DES, IVascular) P. Goverde MD, K. Taeymans MD, K. Lauwers MD Vascular Clinic ZNA Antwerp,Belgium
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationDo the newest grafts achieve comparable results to saphenous vein bypass? THE HEPARIN-BONDED eptfe GRAFT. C. Pratesi
Do the newest grafts achieve comparable results to saphenous vein bypass? THE HEPARIN-BONDED eptfe GRAFT C. Pratesi Department of Vascular Surgery University of Florence-Italy www.chirvasc-unifi.it FEMORO-POPLITEAL
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationIMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of
IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of referenced technologies as well as current standards of care
More information3-year results of the OLIVE registry:
3-year results of the OLIVE registry: A prospective multicenter study in patients with critical limb ischemia Osamu Iida, MD Kansai Rosai Hospital Cardiovascular Center Amagasaki, Hyogo, Japan Disclosure
More informationHiroshi Ando, MD Kasukabe Chuo General Hospital Saitama, Japan
Hiroshi Ando, MD Kasukabe Chuo General Hospital Saitama, Japan Disclosure Hiroshi Ando, MD Kasukabe Chuo General Hospital I have the following potential conflicts of interest to report: Consulting Employment
More informationPractical Point in Diabetic Foot Care 3-4 July 2017
Diabetic Foot Ulcer : Role of Vascular Surgeon Practical Point in Diabetic Foot Care 3-4 July 2017 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai University
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationGLOBAL VASCULAR GUIDELINES: A NEW PATHWAY FOR LIMB SALVAGE
GLOBAL VASCULAR GUIDELINES: A NEW PATHWAY FOR LIMB SALVAGE Michael S. Conte MD Professor and Chief, Vascular and Endovascular Surgery Co-Director, Center for Limb Preservation Co-Director, Heart and Vascular
More informationEndovascular Options in Critical Limb Ischemia: Below The Knee Therapies
Endovascular Options in Critical Limb Ischemia: Below The Knee Therapies Bret N. Wiechmann, MD FSIR FAHA FSVM Vascular & Interventional Physicians Gainesville, Florida Disclosures Consultant: Medcomp Bard
More informationClinical Approach to CLI and Related Diagnostics: What You Need to Know
Clinical Approach to CLI and Related Diagnostics: What You Need to Know Ido Weinberg, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital None Disclosures Critical
More informationUC SF. Disclosures. Vascular Assessment of the Diabetic Foot. What are the best predictors of wound healing? None. Non-Invasive Vascular Studies
Disclosures Vascular Assessment of the Diabetic Foot What are the best predictors of wound healing? None Shant Vartanian MD Assistant Professor of Vascular Surgery UCSF Vascular Symposium April 20, 2013
More informationClinical presentation and outcome after failed infrainguinal endovascular and open revascularization in patients with chronic limb ischemia
From the Society for Clinical Vascular Surgery Clinical presentation and outcome after failed infrainguinal endovascular and open revascularization in patients with chronic limb ischemia Hasan H. Dosluoglu,
More informationDrug-Eluting Balloon Angioplasty versus Bare Metal Stents for Femoropopliteal Disease in Real-World Experience
Drug-Eluting Balloon Angioplasty versus Bare Metal Stents for Femoropopliteal Disease in Real-World Experience Maria Doyle, M.Eng; Hilary Coffey, M.D. Ravindra Gullipalli, MBBS, FRCR St. Clare s Mercy
More informationCan t See the Forest for the Trees: Transcollateral Crossing of Chronic Total Occlusions
Can t See the Forest for the Trees: Transcollateral Crossing of Chronic Total Occlusions Vinayak Subramanian, BS 1 ; George L. Adams, MD, MHS 2 From 1 Department of Biomedical Engineering, North Carolina
More informationWhat Happened in the IN.PACT Deep Trial. Zaheed Tai, DO,FACC,FSCAI Bos4ck Heart Center Winter Haven, FL
What Happened in the IN.PACT Deep Trial Zaheed Tai, DO,FACC,FSCAI Bos4ck Heart Center Winter Haven, FL BTK Revasculariza>on Challenges Long, complex, ocen calcified nature of lesions 1 OCen associated
More informationPAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014
PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014 Van Crisco, MD, FACC, FSCAI First Coast Heart and Vascular Center, PLLC Jacksonville, FL 678-313-6695 Conflict of Interest Bayer Healthcare
More informationObjective assessment of CLI patients Hemodynamic parameters
Objective assessment of CLI patients Hemodynamic parameters Worth anything in end stage patients? Marianne Brodmann Angiology, Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann
More informationSurgical Bypass or. Zilver PTX. 12 months preliminary data. LINC 2016, Leipzig. Marc Bosiers, MD. Marc Bosiers Koen Deloose Joren Callaert
LINC 2016, Leipzig Surgical Bypass or A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Patrick Peeters Jürgen Verbist Wouter Van den Eynde OLV Hospital,
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report G. Biro, M. Bosiers on behalf of ZILVERPASS Study Group Disclosure Speaker
More informationEfficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
More informationEndovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial
Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial Prof. Thomas Zeller, MD Department Angiology Clinic for Cardiology and Angiology II University Heart-Center
More informationManaging Conditions Resulting from Untreated Cardiometabolic Syndrome
Managing Conditions Resulting from Untreated Cardiometabolic Syndrome Matthew P. Namanny DO, FACOS Vascular/Endovascular Surgery Saguaro Surgical/AZ Vascular Specialist Tucson Medical Center Critical Limb
More informationLUTONIX DCB in BTK Update on the BTK clinical program & single center experience
LUTONIX DCB in BTK Update on the BTK clinical program & single center experience Prof. Dr. med. Dierk Scheinert Department of Interventional Angiology University Hospital Leipzig Disclaimer 1. The information
More informationExtreme SFA Lesions: DETOUR I 12- Month Results in Lesions >30cm. Sean Lyden, MD Chairman Vascular Surgery Cleveland Clinic Cleveland, Ohio
Extreme SFA Lesions: DETOUR I 12- Month Results in Lesions >30cm Sean Lyden, MD Chairman Vascular Surgery Cleveland Clinic Cleveland, Ohio Extreme SFA Lesions: DETOUR I 12-Month Results in Lesions >30cm
More informationDisclosures. In-Stent Restenosis: The Tail IS Wagging the Dog 4/15/2016. Restenosis: The Continuing Challenge for Peripheral Vascular Intervention
In-Stent Restenosis: The Tail IS Wagging the Dog Disclosures NONE Michael S. Conte MD Division of Vascular and Endovascular Surgery UCSF Heart and Vascular Center UCSF Vascular Symposium 2016 IF YOU WERE
More informationNurse and Technician Forum Part II Critical Limb Ischemia: Optimal care, an interdisciplinary challenge
L E I P Z I G I N T E R V E N T I O N A L C O U R S E 2017 Nurse and Technician Forum Part II Critical Limb Ischemia: Optimal care, an interdisciplinary challenge Markus Haumer Landesklinikum Baden-Mödling
More informationCritical Limb Ischemia A Collaborative Approach to Patient Care. Christopher LeSar, MD Vascular Institute of Chattanooga July 28, 2017
Critical Limb Ischemia A Collaborative Approach to Patient Care Christopher LeSar, MD Vascular Institute of Chattanooga July 28, 2017 Surgeons idea Surgeons idea represents the final stage of peripheral
More informationWifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization
Wifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization A Sonetto, M Abualhin, M Gargiulo, GL Faggioli, A Stella Disclosure Speaker
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationComparison of angioplasty and bypass surgery for critical limb ischaemia in patients with infrapopliteal peripheral artery disease
Original article Comparison of angioplasty and bypass surgery for critical limb ischaemia in patients with infrapopliteal peripheral artery disease S. D. Patel 1,L.Biasi 1, I. Paraskevopoulos 2, J. Silickas
More informationA Case for Mandatory Routine Graft Surveillance of lower extremity bypass grafts. Avishai Meyer UCHSC resident, Surgery May 8, 2006
A Case for Mandatory Routine Graft Surveillance of lower extremity bypass grafts Avishai Meyer UCHSC resident, Surgery May 8, 2006 Outline: Definition Background of terms and studies U/S surveillance What
More informationOutcomes of Critical Limb Ischemia in Hemodialysis Patients After Distal Bypass Surgery
2382 HOSHINA K et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Peripheral Vascular Disease Outcomes of Critical Limb Ischemia in
More informationPAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler Jones, MD September 14, 2016
PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler, MD September 14, 2016 Interventional Cardiology and Cath Labs Disclosures Research Grants: Agency for Healthcare Research
More informationDue to Perimed s commitment to continuous improvement of our products, all specifications are subject to change without notice.
A summary Disclaimer The information contained in this document is intended to provide general information only. It is not intended to be, nor does it constitute, medical advice. Under no circumstances
More informationDisclosures. Tips and Tricks for Tibial Intervention. Tibial intervention overview
Tips and Tricks for Tibial Intervention Donald L. Jacobs, MD C Rollins Hanlon Endowed Professor and Chair Chair of Surgery Saint Louis University SSM-STL Saint Louis University Hospital Disclosures Abbott
More informationValidation and Clinical Utility of the SVS WIfI Threatened Limb Classification
Validation and Clinical Utility of the SVS WIfI Threatened Limb Classification PRESENTED BY: 11 th Houston Aortic Symposium 15 February 2018 Joseph L. Mills, Sr., M.D. Reid Endowed Professor of Surgery
More informationRobert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015
Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015 Disclosure I have nothing to disclose Randomized Controlled Studies In SFA Technology: What s The Best Tool For
More informationAccess strategy for chronic total occlusions (CTOs) is crucial
Learn How Access Strategy Impacts Complex CTO Crossing Arthur C. Lee, MD The Cardiac & Vascular Institute, Gainesville, Florida VASCULAR DISEASE MANAGEMENT 2018;15(3):E19-E23. Key words: chronic total
More informationUse of Laser In BTK Disease (CLI)
Use of Laser In BTK Disease (CLI) Click to edit academic affiliation, practice or hospital logo(s) of preference. Product and/or sponsor logos not permitted, per CME guidelines. Richard Kovach, MD, FACC,
More informationDisclosures. Critical Limb Ischemia. Vascular Testing in the CLI Patient. Vascular Testing in Critical Limb Ischemia UCSF Vascular Symposium
Disclosures Vascular Testing in the CLI Patient None 2015 UCSF Vascular Symposium Warren Gasper, MD Assistant Professor of Surgery UCSF Division of Vascular Surgery Critical Limb Ischemia Chronic Limb
More informationClasificación WIFI: Finalmente hablaremos el mismo idioma! WIfI: Wound, Ischemia, foot Infection The SVS Threatened Limb Classification
Clasificación WIFI: Finalmente hablaremos el mismo idioma! WIfI: Wound, Ischemia, foot Infection The SVS Threatened Limb Classification Joseph L. Mills, Sr., M.D. Professor of Surgery, Chief, Vascular
More informationContemporary use of DCBs, Ranger clinical trial and investigator sponsored research
Contemporary use of DCBs, Ranger clinical trial and investigator sponsored research Dierk Scheinert, MD Division of Interventional Angiology University-Hospital, Leipzig, Germany IMPORTANT INFORMATION:
More informationPedal Bypass With Deep Venous Arterialization:
Pedal Bypass With Deep Venous Arterialization: Long Term Result For Critical Limb Ischemia With Unreconstructable Distal Arteries Pramook Mutirangura Professor of Vascular Surgery Faculty of Medicine Siriraj
More information